KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Payables (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Payables for 9 consecutive years, with $15.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 35.92% year-over-year to $15.8 million, compared with a TTM value of $15.8 million through Dec 2025, up 35.92%, and an annual FY2025 reading of $15.8 million, up 35.92% over the prior year.
  • Payables was $15.8 million for Q4 2025 at Biocryst Pharmaceuticals, up from $5.6 million in the prior quarter.
  • Across five years, Payables topped out at $20.9 million in Q4 2023 and bottomed at $5.6 million in Q3 2025.
  • Average Payables over 3 years is $11.4 million, with a median of $11.1 million recorded in 2023.
  • The sharpest move saw Payables surged 90.44% in 2024, then plummeted 58.71% in 2025.
  • Year by year, Payables stood at $20.9 million in 2023, then crashed by 44.27% to $11.6 million in 2024, then soared by 35.92% to $15.8 million in 2025.
  • Business Quant data shows Payables for BCRX at $15.8 million in Q4 2025, $5.6 million in Q3 2025, and $8.6 million in Q2 2025.